The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pulmonary Arterial Hypertension (PAH) Industry" - https://www.reportlinker.com/p06417528/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Pulmonary Arterial Hypertension (PAH) Market to Reach $9.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Pulmonary Arterial Hypertension (PAH) estimated at US$6.8 Billion in the year 2022, is projected to reach a revised size of US$9.8 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2022-2030. Prostacyclin & Prostacyclin Analogs, one of the segments analyzed in the report, is projected to record a 4.2% CAGR and reach US$4.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Endothelin Receptor Antagonists (ERAs) segment is readjusted to a revised 5.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 7.9% CAGR

The Pulmonary Arterial Hypertension (PAH) market in the U.S. is estimated at US$1.9 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 3.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2030.

Select Competitors (Total 23 Featured)
- Actelion Pharmaceuticals Ltd.
- Bayer AG
- Gilead Sciences, Inc.
- Lung Biotechnology PBC
- Pfizer Inc.
- United Therapeutics Corporation


Read the full report: https://www.reportlinker.com/p06417528/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Pulmonary Arterial Hypertension (PAH) - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Pulmonary Arterial
Hypertension (PAH) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2021 and % CAGR

Table 3: World 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Prostacyclin & Prostacyclin Analogs by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Prostacyclin & Prostacyclin
Analogs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2021 and % CAGR

Table 6: World 18-Year Perspective for Prostacyclin &
Prostacyclin Analogs by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Endothelin Receptor Antagonists (ERAs) by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Endothelin Receptor
Antagonists (ERAs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2021 and % CAGR

Table 9: World 18-Year Perspective for Endothelin Receptor
Antagonists (ERAs) by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for SGC
Stimulators by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for SGC Stimulators by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 12: World 18-Year Perspective for SGC Stimulators by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
PDE-5 Inhibitors by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for PDE-5 Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 15: World 18-Year Perspective for PDE-5 Inhibitors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Branded by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Branded by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 18: World 18-Year Perspective for Branded by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Generics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Generics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 21: World 18-Year Perspective for Generics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for Oral
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 23: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR

Table 24: World 18-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Intravenous / Subcutaneous by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Intravenous / Subcutaneous
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 27: World 18-Year Perspective for Intravenous /
Subcutaneous by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis for
Inhalational by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 29: World Historic Review for Inhalational by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 30: World 18-Year Perspective for Inhalational by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030

Table 31: World Pulmonary Arterial Hypertension (PAH) Market
Analysis of Annual Sales in US$ Million for Years 2012 through
2030

III. MARKET ANALYSIS

UNITED STATES
Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2023 (E)
Table 32: USA Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 33: USA Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 34: USA 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 35: USA Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 36: USA Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 37: USA 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 38: USA Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 39: USA Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 40: USA 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

CANADA
Table 41: Canada Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 42: Canada Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 43: Canada 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 44: Canada Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 45: Canada Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 46: Canada 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 47: Canada Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 48: Canada Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 49: Canada 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

JAPAN
Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 50: Japan Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 51: Japan Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 52: Japan 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 53: Japan Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 54: Japan Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 55: Japan 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 56: Japan Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 57: Japan Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 58: Japan 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

CHINA
Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 59: China Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 60: China Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 61: China 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 62: China Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 63: China Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 64: China 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 65: China Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 66: China Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 67: China 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

EUROPE
Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 68: Europe Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Geographic Region -
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 69: Europe Historic Review for Pulmonary Arterial
Hypertension (PAH) by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 70: Europe 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Geographic Region - Percentage Breakdown
of Value Sales for France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets for Years 2012, 2023 & 2030

Table 71: Europe Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 72: Europe Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 73: Europe 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 74: Europe Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 75: Europe Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 76: Europe 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 77: Europe Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 78: Europe Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 79: Europe 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

FRANCE
Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 80: France Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 81: France Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 82: France 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 83: France Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 84: France Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 85: France 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 86: France Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 87: France Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 88: France 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

GERMANY
Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2023:
( E)
Table 89: Germany Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 90: Germany Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 91: Germany 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 92: Germany Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 93: Germany Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 94: Germany 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 95: Germany Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 96: Germany Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 97: Germany 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

ITALY
Table 98: Italy Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 99: Italy Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 100: Italy 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 101: Italy Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 102: Italy Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 103: Italy 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 104: Italy Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 105: Italy Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 106: Italy 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

UNITED KINGDOM
Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2023 (E)
Table 107: UK Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 108: UK Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 109: UK 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Percentage Breakdown of
Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin
Receptor Antagonists (ERAs), SGC Stimulators and PDE-5
Inhibitors for the Years 2012, 2023 & 2030

Table 110: UK Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Type - Branded and
Generics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 111: UK Historic Review for Pulmonary Arterial
Hypertension (PAH) by Type - Branded and Generics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 112: UK 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Type - Percentage Breakdown of Value
Sales for Branded and Generics for the Years 2012, 2023 & 2030

Table 113: UK Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Route Of
Administration - Oral, Intravenous / Subcutaneous and
Inhalational - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 114: UK Historic Review for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Oral,
Intravenous / Subcutaneous and Inhalational Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 115: UK 18-Year Perspective for Pulmonary Arterial
Hypertension (PAH) by Route Of Administration - Percentage
Breakdown of Value Sales for Oral, Intravenous / Subcutaneous
and Inhalational for the Years 2012, 2023 & 2030

SPAIN
Table 116: Spain Recent Past, Current & Future Analysis for
Pulmonary Arterial Hypertension (PAH) by Drug Class -
Prostacyclin & Prostacyclin Analogs, Endothelin Receptor
Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 117: Spain Historic Review for Pulmonary Arterial
Hypertension (PAH) by Drug Class - Prostacyclin & Prostacyclin
Analogs, Endothelin Receptor Antagonists (ERAs), SGC
Stimulators and PDE-5 Inhibitors Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06417528/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001